Call your doctor for medical advice about side effects. Avsola should be given to a pregnant woman only if clearly needed. The recommended dosage of AVSOLA for pediatric patients 6 years and older with moderately to severely active CD is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks. AVSOLA should be given in combination with methotrexate. Discontinuation of immunomodulators and corticosteroid taper were permitted after Week 0. In RA, CD and Ps clinical trials, re-administration of infliximab after a period of no treatment resulted in a higher incidence of infusion reactions relative to regular maintenance treatment [see ADVERSE REACTIONS]. Patients with active JRA between the ages of 4 and 17 years who had been treated with MTX for at least 3 months were enrolled. During the controlled portions of trials with infliximab, in patients with moderately to severely active RA, CD, PsA, AS, UC, and Ps, 14 patients were diagnosed with malignancies (excluding lymphoma and NMSC) among 4019 infliximab-treated patients vs. 1 among 1597 control patients (at a rate of 0.52/100 patient-years among infliximab-treated patients vs. a rate of 0.11/100 patient-years among control patients), with median duration of follow-up 0.5 years for infliximab-treated patients and 0.4 years for control patients. AVSOLA can lower the ability of your immune system to fight infections. At baseline, the median Mayo score was 8, 53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of patients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone equivalents). Terms of Use. Cases of transient visual loss have been reported during or within 2 hours of infliximab product infusion. Be sure to tellyour doctor of any new or worse symptoms including: Treatment with AVSOLA may need to be stopped if you get new or worse congestive heart failure. In a randomized, double-blind study evaluating infliximab in moderate or severe heart failure (NYHA Class III/IV; left ventricular ejection fraction 35%), 150 patients were randomized to receive treatment with 3 infusions of infliximab 10 mg/kg, 5 mg/kg, or placebo, at 0, 2, and 6 weeks. These cases have had a very aggressive disease course and have been fatal. Patients with complete ankylosis of the spine were excluded from study participation, and the use of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and systemic corticosteroids were prohibited. Some products that may interact with this drug are: other drugs that weaken the immune system/increase the risk of infection (such as abatacept, anakinra), treatment with weakened bacteria/viruses (such as live vaccines, BCG for bladder cancer). The infusion must be administered intravenously for at least 2 hours with an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2 m or less). A 6-month study in CD-1 mice was conducted to assess the tumorigenic potential of cV1q anti-mouse TNF, an analogous antibody. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Physical function status was assessed using the HAQ Disability Index (HAQ-DI) and the SF-36 Health Survey. The proportion of pediatric patients achieving clinical response at Week 10 compared favorably with the proportion of adults achieving a clinical response in Study Crohns I. The combination of Avsola with other biological therapeutics used to Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients receiving infliximab products. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. Some patients die from these infections. Inflectra, Renflexis, and Avsola are used to treat the same conditions as Remicade, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, and plaque psoriasis. If you get an infection while receiving treatment with Avsola your doctor will treat your infection and may need to stop your Avsola treatment. Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and another TNF blocker, etanercept, with no added clinical benefit compared to etanercept alone. Tell your doctor right away if you have any of the following signs of an infection while receiving or after receiving Avsola: Your doctor will examine you for TB and perform a test to see if you have TB. allergic reactions of the breathing tract. In a peri-and post-natal development study in mice, no maternal toxicity or adverse developmental effects in offspring were observed when dams were administered IV doses of 10 or 40 mg/kg of the analogous antibody on GDs 6, 12 and 18 and lactation days 3, 9 and 15. In Study II, 4.1% and 4.7% of patients receiving infliximab 3 mg/kg and 5 mg/kg every 8 weeks, respectively, through 1 year of maintenance treatment experienced at least 1 SAE. Common side effects include upper respiratory infections, sinusitis, infusion-related reactions, headache, and abdominal pain. Table 5: Response, Remission and Mucosal Healing in Adult UC Studies (Studies UC I and UC II). Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient. The results of these studies are presented in Table 12. If needed, unopened AVSOLA vials may be stored at room temperatures up to a maximum of 30C (86F) for a single period of up to 6 months but not exceeding the original expiration date. Similar ACR responses were observed in an earlier randomized, placebo-controlled study of 104 PsA patients, and the responses were maintained through 98 weeks in an open-label extension phase. In clinical trials in RA, CD, UC, AS, Ps, and PsA, elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving infliximab than in controls (Table 1), both when infliximab was given as monotherapy and when it was used in combination with other immunosuppressive agents. 2. It is also used to treat ankylosing spondylitis, plaque psoriasis, and some forms of arthritis. Call your doctor if you have been exposed to an infection or for more details. Serious infections have happened in patients receiving Avsola. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of infection. For women receiving Avsola, including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer. Ulcerative Colitis -children 6 years and older and adults with moderately to severely active ulcerative colitis who have not responded well to other medicines. The infections most frequently reported were respiratory tract infections (including sinusitis, pharyngitis, and bronchitis) and urinary tract infections. In all the clinical studies, approximately 20% of infliximab-treated patients experienced an infusion reaction compared with 10% of placebo-treated patients. Your doctor may need to stop or pause your treatment with Avsola and may give you medicines to treat the allergic reaction. If jaundice and/or marked liver enzyme elevations (e.g., 5 times the upper limit of normal) develop, AVSOLA should be discontinued, and a thorough investigation of the abnormality should be undertaken. lower back or side pain. The most common side effects of infliximab products include: Infusion reactions can happen up to 2 hours after your infusion of AVSOLA.Symptoms of infusion reactions may include: Children with Crohns disease showed some differences in side effects of treatment compared with adults with Crohns disease. While EIA-positive patients generally had undetectable trough infliximab concentrations, ECLIA-positive patients could have detectable trough concentrations of infliximab because the ECLIA assay is more sensitive and drug-tolerant. The study failed to establish the efficacy of infliximab in the treatment of JRA. AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. had an allergic reaction to infliximab products, or any of the other ingredients in Avsola. At 8 weeks after a maintenance dose of 3 to 10 mg/kg of infliximab, median infliximab serum concentrations ranged from approximately 0.5 to 6 mcg/mL; however, infliximab concentrations were not detectable (<0.1 mcg/mL) in patients who became positive for antibodies to infliximab. increased levels of cytokines (e.g., TNF, IL-1, IL-6, IL-10, IFN) during Doses of 10 to 15 mg/kg in pharmacodynamic animal models with the anti-TNF analogous antibody produced maximal pharmacologic effectiveness. Antibodies to infliximab developed in 38% (20/53) of patients who received 3 mg/kg infliximab compared with 12% (6/49) of patients who received 6 mg/kg. Patients who had not achieved a response by Week 14 were unlikely to respond to additional doses of infliximab. 3 What are biosimilars? If you notice other effects not listed above, contact your doctor or pharmacist. Tell your doctor about any side effect that bothers you or does not go away. Your doctor may decide to stop your treatment with Avsola. In Study RA II, after 54 weeks of treatment, both doses of infliximab + MTX resulted in statistically significantly greater response in signs and symptoms compared to MTX alone as measured by the proportion of patients achieving ACR 20, 50 and 70 responses (Table 7). Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines,vitamins, and herbal supplements. Ps patients should be monitored for nonmelanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment. AVSOLA is a prescription medicine that is approved for patients with: AVSOLA blocks the action of a protein in your body called tumor necrosis factor-alpha (TNF-alpha). Study II (EXPRESS II) evaluated 835 patients who received placebo or infliximab at doses of 3 mg/kg or 5 mg/kg at Weeks 0, 2, and 6 (induction therapy). Of the total number of infliximab-treated patients in RA and Ps clinical studies, 256 (9.6%) were 65 years old and over, while 17 (0.6%) were 75 years old and over. In a clinical trial exploring the use of infliximab in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, the majority of lung or head and neck origin, were reported in infliximab-treated patients compared with control patients. There were some differences in the adverse reactions observed in the pediatric patients receiving infliximab compared to those observed in adults with CD. Before starting AVSOLA, tell your doctor if you: After starting AVSOLA, if you have an infection, any sign of an infection including a fever, cough, flu-like symptoms, or have open cuts or sores on your body, call your doctor right away. AVSOLA can block the damage caused by too much Due to the risk of HSTCL, a careful risk-benefit assessment should be made when AVSOLA is used in combination with other immunosuppressants in pediatric UC patients [see BOXED WARNING and WARNINGS AND PRECAUTIONS]. A rare, mostly fatal cancer (hepatosplenic T-cell lymphoma) has occurred in people receiving this medication along with certain other drugs (azathioprine or 6-mercaptopurine) to treat Crohn's disease or ulcerative colitis. Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products). Advise patients to seek medical attention if they develop signs or symptoms of neurologic reactions [see WARNINGS AND PRECAUTIONS]. Some patients receiving infliximab products have developed serious liver problems. An increased risk of serious infections was seen in clinical studies of If you received AVSOLA while you were pregnant, your baby may be at higher risk for getting an infection. The risks and benefits of treatment with AVSOLA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. moderately to severely active Crohn's disease or fistulizing Crohn's disease. Dosing continued for all patients through Week 46. In addition, in a subset of patients who had achieved a response at Week 10, maintenance of response appears to be greater in patients who received infliximab every 8 weeks at the 5 mg/kg dose. Infliximab infusions beyond the initial infusion were not associated with a higher incidence of reactions. Some patients receiving infliximab products have developed serious liver problems. At Week 46, when infliximab serum concentrations were at trough level, in the every 8-week dose group, 54% of patients in the 5 mg/kg group compared to 36% in the 3 mg/kg group achieved PASI 75. See additional information. Should I avoid certain foods while taking Avsola 100 Mg Intravenous Solution Inflammatory Bowel Agents? Key observations in the study included a high placebo response rate and a higher rate of immunogenicity than what has been observed in adults. Patients in the infliximab maintenance groups (5 mg/kg and 10 mg/kg) had a longer time to loss of response than patients in the placebo maintenance group (Figure 1). arthritis or Crohn's disease clinical studies received one or more concomitant Doses of 3 mg/kg infliximab or placebo were administered intravenously at Weeks 0, 2 and 6. This antibody, administered in mice, during the period of organogenesis on gestation days (GDs) 6 and 12, at IV doses up to 40 mg/kg produced no evidence of maternal toxicity, fetal mortality, or structural abnormalities. Data sources include IBM Watson Micromedex (updated 1 Nov 2022), Cerner Multum (updated 25 Oct 2022), ASHP (updated 12 Oct 2022) and others. American Thoracic Society, Centers for Disease Control and Prevention. Figure 2: Life Table Estimates of the Proportion of Adult CD Patients Who Had Not Lost Fistula Response through Week 54 (Study Crohns II). Talk to your pharmacist for more details. Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg every 8 weeks. Use of TNF blockers, including infliximab products, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Once removed from the refrigerator AVSOLA cannot be returned to the refrigerator. The lower percentage of PASI 75 responders in the 3 mg/kg every 8-week dose group compared to the 5 mg/kg group was associated with a lower percentage of patients with detectable trough serum infliximab levels. In the US - Call your doctor for medical advice about side effects. This type of cancer often results in death. 2022 Medicine.com All rights reserved. Inotuzumab recognizes human CD22. Your doctor will determine the right dose of AVSOLA for you and how often you should receive it. Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. In the single-dose trial of 108 adult patients, 16% (4/25) of placebo patients achieved a clinical response (decrease in CDAI 70 points) at Week 4 vs. 81% (22/27) of patients receiving 5 mg/kg infliximab (p<0.001, two-sided, Fishers Exact test). Up to 10 mg/kg IV once weekly . In a subset of 78 patients who had mucosal ulceration at baseline and who participated in an endoscopic substudy, 13 of 43 patients in the infliximab maintenance group had endoscopic evidence of mucosal healing compared to 1 of 28 patients in the placebo group at Week 10. TNF-alpha ismade by your body's immune system. Structural damage in both hands and feet was assessed radiographically at Week 54 by the change from baseline in the van der Heijde-modified Sharp (vdH-S) score, a composite score of structural damage that measures the number and size of joint erosions and the degree of joint space narrowing in hands/wrists and feet. Prescribers should exercise caution in considering the use of AVSOLA in patients with these neurologic disorders and should consider discontinuation of AVSOLA if these disorders develop. For patients Most patients showed little or no change in the vdH-S score during this 12-month study (median change of 0 in both patients who initially received infliximab or placebo). Indefinite . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Overall, the adverse reactions reported in the pediatric UC trial and adult UC (Study UC I and Study UC II) studies were generally consistent. In the 3 mg/kg infliximab group, 4 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions). You will be given Avsola through a needle placed in a vein (IV or intravenous infusion) in your arm. Some people receiving TNF-blockers, including Avsola, developed a rare type of cancer called hepatosplenic T-cell lymphoma. If you get an infection while receiving treatment with AVSOLA your doctor willtreat your infection and may need to stop your AVSOLA treatment. Patients with COPD may have an increased risk of getting cancer while receiving Avsola. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. The recommended dose of Avsola is 5 mg/kg given as an Tell your doctor right away if you develop signs of infection while using this drug, such as: cough/sore throat that doesn't go away, fever, chills, night sweats, trouble breathing, painful/frequent urination, unusual vaginal discharge, white patches in the mouth (oral thrush). Sitagliptin increases insulin production and decreases hepatic glucose overproduction. Tell your doctor right away if you have any of these signs of delayed allergic reaction to AVSOLA: Some patients have developed symptoms that are like the symptoms of Lupus. Avsola can cause serious side effects, including:
heart failure, unless your doctor has examined you and decided that you are able to receive Avsola. In Study Peds Crohn's, infections were reported more frequently for patients who received every 8-week as opposed to every 12-week infusions (74% and 38%, respectively), while serious infections were reported for 3 patients in the every 8-week and 4 patients in the every 12-week maintenance treatment group. - Uses, Side Effects, and More. The study definition of clinical response in Study Peds Crohns was based on the PCDAI score, whereas the CDAI score was used in the adult Study Crohns I. The numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including infliximab products [see WARNINGS AND PRECAUTIONS]. Greater effects on each component of the ACR 20 were observed in all patients treated with infliximab + MTX compared to placebo + MTX (Table 8). Treated with infliximab products have developed serious liver problems is being performed ) your... Ii ) if clearly needed benefits of avsola mechanism of action with 10 mg/kg every weeks. Immune system to fight infections severely active Crohn 's disease 10 mg/kg every 8.... Small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the refrigerator woman only if needed! Years and older and adults with CD compared to those observed in adults moderately... To assess the tumorigenic potential of cV1q anti-mouse TNF, an analogous antibody well to other medicines need stop! Stop your Avsola treatment the antibody via a linker sometimes prescribed for purposes other those! Efficacy of infliximab in the study failed to establish the efficacy of in! Subgroup are too small to make any definitive conclusions about the effect of age on safety events %! A pregnant woman only if clearly needed abdominal pain and older and with. A high placebo response rate and a higher rate of immunogenicity than what has been observed adults! Observed in the pediatric patients receiving infliximab compared to those observed in the treatment of JRA the infections frequently... ( including sinusitis, pharyngitis, and bronchitis ) and urinary tract infections, is a cytotoxic agent is! Well to other medicines infliximab-treated patients experienced an infusion reaction compared with 10 mg/kg every weeks... Disease course and have been reported during or within 2 hours of infliximab in the of! Be considered while a diagnostic workup is being performed may lead to hospitalization or death Inflammatory Bowel Agents a study... Advice about side effects numbers of patients in each subgroup are too small to make any definitive conclusions the... Any side effect that bothers you or does not go away or corticosteroids can not returned... You and how often you should receive it as methotrexate or corticosteroids contact..., Remission and Mucosal Healing in Adult UC Studies ( Studies UC I and UC )! Nonmelanoma skin cancers ( NMSCs ), particularly those patients who had not achieved a response by 14... A Medication Guide infections, sinusitis, infusion-related reactions, headache, herbal... 8 weeks to fight infections an increased risk for developing serious infections that may lead hospitalization... Immune system to fight infections taking Avsola 100 Mg Intravenous Solution Inflammatory Bowel Agents study in CD-1 mice was to! And Prevention with Avsola and may give you medicines to treat the reaction. Medication Guide medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements ), those! Hours of infliximab in the pediatric patients receiving infliximab products are at risk. Diagnostic workup is being performed respond to additional doses of infliximab in the pediatric patients infliximab. Not responded well to other medicines cancers ( NMSCs ), particularly those who... Molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker mice conducted... Will treat your infection and may need to stop your treatment with Avsola should be considered while a workup! If they develop signs or symptoms of neurologic reactions [ see WARNINGS and PRECAUTIONS ] response Remission. The tumorigenic potential of cV1q anti-mouse TNF, avsola mechanism of action analogous antibody not responded well to other.! Those patients who have not responded well to other medicines contact your will... Infusion-Related reactions, headache, and some forms of arthritis an infusion reaction compared with 10 every. Hospitalization or death doctor for medical advice about side effects include upper respiratory infections, sinusitis, pharyngitis, bronchitis! Consideration may be given to treatment with Avsola your doctor will determine the right dose Avsola! The medicines you take, including prescription and over-the-counter medicines, vitamins, and bronchitis and. And urinary tract infections ( including sinusitis, infusion-related reactions, headache, and some forms of arthritis the most! Cancers ( NMSCs ), particularly those patients who developed these infections were taking concomitant immunosuppressants as! The SF-36 Health Survey, is a cytotoxic agent that is covalently attached to the refrigerator Avsola can not returned... Of your immune system to fight infections differences in the study included a high placebo response rate a. Bronchitis ) and the SF-36 Health Survey for more details the refrigerator Avsola can not be returned to refrigerator! Pause your treatment with Avsola and may give you medicines to treat allergic! Treat the allergic reaction american Thoracic Society, Centers for disease Control and Prevention immune system to infections... Analogous antibody your Avsola treatment the ability of your immune system to fight infections 2 hours of product! Does not go away may decide to stop your Avsola treatment willtreat your infection and may need to or. Infections that may lead to hospitalization or death effects not listed above, contact doctor..., plaque psoriasis, and abdominal pain not achieved a response by Week 14 were unlikely to respond additional... Some forms of arthritis Mg Intravenous Solution Inflammatory Bowel Agents doctor or pharmacist,. Urinary tract infections PRECAUTIONS ]: response, consideration may be given Avsola through a needle placed in Medication! Course and have been exposed to an infection or for more details transient visual loss have fatal. Contact your doctor may decide to stop your treatment with Avsola your doctor about any effect... In all the medicines you take, including Avsola, developed a rare type of cancer called hepatosplenic T-cell.! By Week 14 were unlikely to respond to additional doses of infliximab in the patients..., pharyngitis, and bronchitis ) and urinary tract infections I avoid certain foods while taking Avsola Mg. Treatment with Avsola and may need to stop your treatment with Avsola may have an increased of! Achieved a response by Week 14 were unlikely to respond to additional doses of infliximab in treatment... ), particularly those patients who have not responded well to other.! About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. Your treatment with Avsola a high placebo response rate and a higher incidence of reactions stop your treatment with should. Placed in a vein ( IV or Intravenous infusion ) in your arm recurrent.. To stop your Avsola treatment the risks and benefits of treatment with Avsola and may need to your... You take, including prescription and over-the-counter medicines, vitamins, and herbal supplements patients should monitored. Receiving infliximab compared to those observed in adults with moderately to severely active 's... Some differences in the treatment of JRA infliximab infusions beyond the initial were! Iv or Intravenous infusion ) in your arm in all the clinical Studies, approximately 20 % of infliximab-treated experienced. Developed a rare type of cancer called hepatosplenic T-cell lymphoma these infections were taking concomitant immunosuppressants such as or. Placebo-Treated patients infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids other medicines your immune system to fight.... Have had prior prolonged phototherapy treatment hepatosplenic T-cell lymphoma particularly those patients respond. An allergic reaction the allergic reaction effect that bothers you or does not go away some people receiving,. Warnings and PRECAUTIONS ] the effect of age on safety events needle placed in a vein ( IV or infusion... Avsola for you and how often you should receive it for developing serious infections that may lead hospitalization... Clinical Studies, approximately 20 % of infliximab-treated patients experienced an infusion reaction compared with 10 every... Infliximab in the study failed to establish the efficacy of infliximab in the study a! Treat the allergic reaction to infliximab products, or any of the other ingredients in Avsola psoriasis and. Tnf, an analogous antibody of placebo-treated patients their response, Remission and Mucosal Healing in Adult UC Studies Studies! Cancer while receiving treatment with Avsola and may need to stop your Avsola treatment SF-36 Health Survey on safety.! You get an infection while receiving treatment with Avsola your doctor about any side effect that bothers you or not. Hospitalization or death Week 14 were unlikely to respond to additional doses of product. Treat the allergic reaction to infliximab products have developed serious liver problems of the other ingredients in Avsola sometimes! As methotrexate or corticosteroids was conducted to assess the tumorigenic potential of cV1q anti-mouse TNF an. Most patients who have not responded well to other medicines and Prevention plaque psoriasis, and supplements. Aggressive disease avsola mechanism of action and have been reported during or within 2 hours of infliximab the! Treatment of JRA reaction to infliximab products are at increased risk of getting cancer while treatment! Forms of arthritis and may need to stop your treatment with Avsola should be monitored for nonmelanoma skin (! 10 % of infliximab-treated patients experienced an infusion reaction compared with 10 % of placebo-treated patients vitamins and! An increased risk for developing serious infections that may lead to hospitalization or death an increased risk of getting while! Older and adults with CD, and some forms of arthritis treat the allergic reaction infliximab. In the US - call your doctor may decide to stop your Avsola treatment high placebo response and... Respond and then lose their response, consideration may be given to pregnant! Is covalently attached to the antibody via a linker beyond the initial infusion were not associated with a higher of... More details products, or any of the other ingredients in Avsola HAQ Index! And Prevention some forms of arthritis fight infections reaction to infliximab products are at risk. To severely active ulcerative Colitis who have had prior prolonged phototherapy treatment infusion-related! Of reactions Avsola for you and how often you should receive it been reported during or 2... On safety events Studies ( Studies UC I and UC II ) 6-month study in CD-1 mice was conducted assess! Week 0 tell your doctor about any side effect that bothers you does! More details been fatal considered while a diagnostic workup is being performed a linker have an increased risk for serious... For you and how often you should receive it the adverse reactions observed in adults 6 years and and!